Abstract
The early initiation of all known treatment strategies for halting the onset and slowing the progression of diabetic neuropathy (DN) is the principal objective in treating a diabetic patient. Prevention and a multidisciplinary approach are essential, given that they contribute to halting progression and decreasing cardiovascular events and the risk of mortality. In recent decades, DN progression rates have slowed, probably due to better control of diabetes and blood pressure (BP), the stabilization or decline in proteinuria favored by renin-angiotensin-aldosterone system (RAAS) inhibitors, and better lipid control. A reduction in the incidence and progression of DN will depend on all of these factors.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
